Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

The Penn Center for Personalized Diagnostics performs large-scale, parallel DNA sequencing and chromosomal analysis to screen hematologic and solid tumors for a wide spectrum of mutations. This video offers a detailed rendering of the workflow for the genomic sequencing process from its initiation at DNA extraction, through the generation and sequencing of an amplicon library via one of two next-generation sequencing (NGS) panels (one for each tumor category) and finally, data analysis through the in-house bioinformatics pipeline wherein the variants are reviewed and interpreted for pathogenicity.

 

 

Related Links


Published

January 19, 2017

Created by

Penn Physician VideoLink